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of end stage renal disease, AMI or stroke are likely to re-
sult in substantial cost-offsets.
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OBJECTIVE: The UK Prospective Diabetes Study (UKPDS)
has proven the relevance of an intensive glucose control
policy in type 2 diabetes. UKPDS 35 has provided the evi-
dence of a significant association between diabetes-related
complications and level of HbA1c. We used the UKPDS
findings to assess the cost-effectiveness of a new fixed-dose
combination of metformin and glibenclamide, compared
to the conventional strategy of the UKPDS.
METHODS: We developed a Markov model reflecting
the management of two diabetic cohorts. The follow-up
of a cohort of newly diagnosed 50-year-old patients, sim-
ilar to the conventional group of the UKPDS, was simu-
lated to follow HbA1c progression over a 10-year period.
The second cohort, treated with metformin-glibencla-
mide, had the same demographic and clinical characteris-
tics at baseline. The reduction rate of HbA1c under met-
formin-glibenclamide was extracted from a 20-week
randomized double-blind trial. The HbA1c level in the
metformin-glibenclamide cohort was assumed to progres-
sively converge with that in the conventional group. The
occurrence of complications was modeled through risk
functions linking HbA1c levels to a conditional probabil-
ity using UKPDS 23 and 35 results. Results were com-
puted in a French context using a payer perspective. Only
medical costs were considered. A sensitivity analysis was
performed on the reduction rate of HbA1c under met-
formin-glibenclamide between 0.8 (best case) and 1.5
(worst case).
RESULTS: Cumulative medical costs amounted to EUR
7,240 in the conventional group versus EUR 7,759 in the
metformin-glibenclamide group. A 6.1% decrease in the
mean number of events per patient was obtained. The ad-
ditional cost per life year saved was EUR 13,142 (9,924
(best case), 17,912 (worst case)) and the additional cost
per complication-free year was EUR 5,736 (4,312 (worst
case), 7,842 (best case)).
CONCLUSION: These results suggest that metformin-
glibenclamide is cost-effective in the treatment of type 2
diabetes when compared with conventional therapy.
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OBJECTIVE: To assess the cost-effectiveness of pioglita-
zone (PIO) based combinations versus alternatives for pa-
tients with type 2 diabetes in Norway.
METHODS: A published/validated model for type1 dia-
betes developed by IMIB was adapted to simulate long-
term management, health outcomes, resource utilisation
and treatment costs of patients with type2 diabetes. The
model accounts for most complications in diabetes pa-
tients: nephropathy; retinopathy; acute myocardial in-
farction; angina pectoris; stroke, and amputation. The
analysis was done from third-party-payer perspective and
costs figured relative to the year 2000. A 5% discount
rate was applied and sensitivity analysis was done to test
the results.
RESULTS: Pioglitazone PIO 30 mg and metformin (MF)
were associated withlonger life expectancy (16.10 years)
than sulphonylureas(SU)/MF (15.24) or rosiglitazone
(RSG)/MET (15.95). PIO 30 mg/SU and PIO 15 mg/SU
are associated with the lowest number of serious compli-
cations per 100 patients treated. For every 95 patients
treated with PIO 30 mg/MF rather than SU/MF or every
27 patients, respectively, for PIO,30 mg/SU rather MF/SU,
one complication is avoided. Combinations of PIO 30
mg/SU, PIO 30 mg/MF and PIO 15 mg/SU are associated
with lower mortality than the other treatment combina-
tions available. Thus, for every 34 patients treated with
PIO 30 mg/MF rather than SU/MF, one death will be
avoided after 15 years of treatment. After discounting
both costs and life years at 5%, the above incremental
cost-per-life-year is 29,406 Norway Kroner (NOK) in
comparison to SU/MF, but still PIO dominates the com-
bination therapy with RSG 8 mg. The picture is similar in
the case of PIO 30 mg/SU combination compared to
MFSU, where in the undiscounted incremental cost per
life year gained, PIO dominates, and the cost per life year
gained is raised to 25,992 NOK after discounting at 5%.
CONCLUSION: Pioglitazone-based treatment for pa-
tients with type2 diabetes improves survival and reduces
complications and therefore represents a cost-effective
use of health-care resources in Norway. Nonetheless,
these results must be confirmed by long-term observa-
tional studies.
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OBJECTIVE: The objective of this study is to assess the
